|Systematic (IUPAC) name|
|AHFS/Drugs.com||Micromedex Detailed Consumer Information|
|Oral (tablets), ophthalmic solution|
|Biological half-life||12 hours|
|ATC code||R06AX17 (WHO) S01GX08 (WHO)|
|Molar mass||309.426 g/mol|
Ketotifen is a second-generation noncompetitive H1-antihistamine and mast cell stabilizer. It is most commonly sold as a salt with fumaric acid, ketotifen fumarate, and is available in two forms. In its ophthalmic form, it is used to treat allergic conjunctivitis, or the itchy red eyes caused by allergies. In its oral form, it is used to prevent asthma attacks.
Ketotifen relieves and prevents eye itchiness and/or irritation associated with most seasonal allergies. It starts working within minutes after administering the drops. The drug has not been studied in children under three. The mean elimination half life is 12 hours. Besides its anti-histaminic activity, it is also a functional leukotriene antagonist and a phosphodiesterase inhibitor.
|This section does not cite any sources. (June 2014) (Learn how and when to remove this template message)|
Side effects include drowsiness, weight gain, dry mouth, irritability, and increased nosebleeds.
Ketotifen is marketed under many brand names worldwide.
- Zaditor prescribing information Novartis
- Grahnén A; Lönnebo A; Beck O; Eckernäs SA; Dahlström B; Lindström B (May 1992). "Pharmacokinetics of ketotifen after oral administration to healthy male subjects". Biopharm Drug Dispos. 13 (4): 255–262. doi:10.1002/bdd.2510130404. PMID 1600111.
- Klooker, TK; Braak, B; Koopman, KE; Welting, O; Wouters, MM; Van Der Heide, S; Schemann, M; Bischoff, SC; et al. (2010). "The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome". Gut. 59 (9): 1213–21. doi:10.1136/gut.2010.213108. PMID 20650926.
- drugs.com International availability of ketofin Page accessed April 21, 2015